Shanghai RAAS controlling shareholder completes shareholding increase plan

Shanghai RAAS Blood Products Co. (Shanghai RAAS) today announced the successful completion of its controlling shareholder's shareholding increase plan. Haiyingkang (Qingdao) Medical Technology Co., the controlling shareholder, accumulated an additional 72,935,300 shares, representing 1.10% of the company's total share capital. The total investment for this increase amounted to approximately 499,991,500 yuan, excluding transaction fees.

The plan, initially disclosed on May 22, 2025, aimed to increase Haiyingkang's stake by a minimum of 250,000,000 yuan and a maximum of 500,000,000 yuan. This initiative was driven by confidence in Shanghai RAAS's future development and long-term investment value, seeking to bolster investor sentiment. Haiyingkang conducted these acquisitions through concentrated bidding on the Shenzhen Stock Exchange between May 22, 2025, and September 15, 2025.

Following the completion of this plan, Haiyingkang's direct shareholding in Shanghai RAAS increased to 1,547,513,352 shares, or 23.31% of the total share capital. Including the voting rights from Grifols, S.A., Haiyingkang and its concerted parties now control 1,984,583,008 shares, representing 29.90% of the voting rights. Haiyingkang has affirmed its commitment not to reduce its shareholding during the lock-up period following this acquisition.